NEW YORK, May 08, 2018 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (Nasdaq:CGIX) in the United States District Court for the District of New Jersey on behalf of a class consisting of investors who purchased or otherwise acquired Cancer Genetics securities on the open market from March 23, 2017 through April 2, 2018, inclusive (the “Class Period”).
Investors who have incurred losses in shares of Cancer Genetics, Inc., you may contact the firm at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the firm on our website, www.whafh.com.
On April 2, 2018, the Company reported that following the departure of its former CEO, it undertook a “comprehensive and extensive review” of its strategy and organization.
As a result, the Company recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable in the fourth quarter of 2017, largely related to “collection issues” with respect to the accounts receivable recorded subsequent to the Company’s 2015 acquisition of Response Genetics Inc.
The Company further disclosed that it “had a Material Weakness in Internal Controls Over Financial Reporting at December 31, 2017” and that its 2017 annual report would contain a going concern qualification.
On this news, Cancer Genetics’ share price fell $0.55 per share, or 33.3%.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 



